Novel drugs targeting the androgen receptor pathway in prostate cancer

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 567-579

  Mateo, Joaquin ^a   Smith, Alan ^a   Ong, Michael ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Androgen receptor; CYP17; Enzalutamide; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER STAGING; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DISCOVERY; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84905124852     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9472-2     Document Type: Review

References (111)

1. White W. (1893). Surgical removal of the hypertrophied prostate. Annals of Surgery, 18, 152-158.
2. Adams, J. (1853). The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet, 1, 393.
3. Huggins, C., & Hodges, C. (1941). The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prosta. Cancer Research, 1, 293-297.
4. Sandow, J., Von Rechenberg, W., Jerzabek, G., & Stoll, W. (1978). Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertility and Sterility, 30, 205-209. (Pubitemid 8383269)
5. The Leuprolide Study Group. (1984). Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. New England Journal of Medicine, 311, 1281-1286.
6. Mainwaring, W. I. (1969). A soluble androgen receptor in the cytoplasm of rat prostate. Journal of Endocrinology, 45, 531-541.
7. Anderson, K. M., & Liao, S. (1968). Selective retention of dihydrotestosterone by prostatic nuclei. Nature, 219, 277-279. 20.
8. Bruchovsky, N., & Wilson, J. D. (1968). The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. Journal of Biological Chemistry, 243, 5953-5960. 25.
9. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., et al. (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine, 321, 419-424. 17.
10. Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., et al. (1996). A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer, 78, 2164-2169. 15.
11. Pienta, K. J., & Bradley, D. (2006). Mechanisms nnderlying the development of androgen-independent prostate cancer. Clinical Cancer Research, 12, 1665-1671. 15.
12. De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364, 1995-2005. 26.
13. Ryan, C. J., Smith, M. R., De Bono, J. S., Molina, A., Logothetis, C. J., De Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368, 138-148. 10.
14. Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187-1197. 27.
15. Cunha, G. R., Ricke, W., Thomson, A., Marker, P. C., Risbridger, G., Hayward, S. W., et al. (2004). Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology, 92, 221-236. (Pubitemid 40136583)
16. Auchus, M. L., & Auchus, R. J. (2012). Human steroid biosynthesis for the oncologist. Journal of Investigative Medicine, 60, 495-503.
17. Sharifi, N., & Auchus, R. J. (2012). Steroid biosynthesis and prostate cancer. Steroids, 77, 719-726.
18. Miller, W. L., & Auchus, R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews, 32, 81-151.
19. Brinkmann, A. O., Klaasen, P., Kuiper, G. G., Van der Korput, J. A., Bolt, J., De Boer, W., et al. (1989). Structure and function of the androgen receptor. Urological Research, 17, 87-93. (Pubitemid 19102601)
20. Klokk, T. I., Kurys, P., Elbi, C., Nagaich, A. K., Hendarwanto, A., Slagsvold, T., et al. (2007). Ligand-specific dynamics of the androgen receptor at its response element in living cells. Molecular and Cellular Biology, 27, 1823-1843.
21. Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New England Journal of Medicine, 332, 1393-1398.
22. Pratt, W. B., & Toft, D. O. (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews, 18, 306-360.
23. Velasco, A. M., Gillis, K. A., Li, Y., Brown, E. L., Sadler, T. M., Achilleos, M., et al. (2004). Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology, 145, 3913-3924. (Pubitemid 39037580)
24. Agoulnik, I. U., & Weigel, N. L. (2009). Coactivator selective regulation of androgen receptor activity. Steroids, 74, 669-674.
25. Attard, G., Belldegrun, A. S., & De Bono, J. S. (2005). Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International, 96, 1241-1246. (Pubitemid 41743917)
26. Brendler, H. (1973). Adrenalectomy and hypophysectomy for prostatic cancer. Urology, 2, 99-102.
27. Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. a., Penning, T. M., et al. (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research, 66, 2815-2825.
28. Montgomery, R. B., Mostaghel, E. a., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68, 4447-4454.
29. Isaacs, J. T., & Coffey, D. S. (1981). Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Research, 41, 5070-5075.
30. Page, S. T., Lin, D. W., Mostaghel, E. a., Hess, D. L., True, L. D., Amory, J. K., et al. (2006). Persistent intraprostatic androgen concentrations after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism, 91, 3850-3856. (Pubitemid 44536854)
31. Donovan, M. J., Osman, I., Khan, F. M., Vengrenyuk, Y., Capodieci, P., Koscuiszka, M., et al. (2010). Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU International, 105, 462-467.
32. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. C., et al. (1999). Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Research, 59, 803-806. 15.
33. Watson, P. a., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., et al. (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 107, 16759-16765. 28.
34. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008). Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research, 68, 5469-5477.
35. Waltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., et al. (2009). Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Research, 69, 8141-8149. 15.
36. Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. a., Picus, J., et al. (2003). Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. Journal of Clinical Oncology, 21, 2673-2678. 15.
37. Matias, P. M., Carrondo, M. A., Coelho, R., Thomaz, M., Zhao, X.-Y., Wegg, A., et al. (2002). Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. Journal of Medicinal Chemistry, 45, 1439-1446. 28.
38. Miller, W. L., Auchus, R. J., & Geller, D. H. (1997). The regulation of 17,20 lyase activity. Steroids, 62, 133-142. (Pubitemid 27066997)
39. Attard, G., Reid, A. H. M., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., et al. (2012). Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. Journal of Clinical Endocrinology and Metabolism, 97, 507-516.
40. Pont, A., Williams, P. L., Azhar, S., Reitz, R. E., Bochra, C., Smith, E. R., et al. (1982). Ketoconazole blocks testosterone synthesis. Archives of Internal Medicine, 142, 2137-2140. (Pubitemid 12007067)
41. Haidar, S., Ehmer, P. B., Barassin, S., Batzl-Hartmann, C., & Hartmann, R. W. (2003). Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. Journal of Steroid Biochemistry and Molecular Biology, 84, 555-562. (Pubitemid 36588809)
42. Reid, A. H., Attard, G., Barrie, E., & De Bono, J. S. (2008). CYP17 inhibition as a hormonal strategy for prostate cancer. Nature Clinical Practice Urology, 5, 610-620.
43. Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994). Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). Journal of Steroid Biochemistry and Molecular Biology, 50, 267-273. (Pubitemid 24309119)
44. Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995). Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry, 38, 2463-2471. 23.
45. Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., et al. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology, 27, 3742-3748. 10.
46. O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., et al. (2004). Hormonal impact of the 17alphahydroxylase/C(17,20)- lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer, 90, 2317-2325. 14.
47. Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., et al. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of Clinical Oncology, 28, 1489-1495. 20.
48. Luthy, I. A., Begin, D. J., & Labrie, F. (1988). Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. Journal of Steroid Biochemistry, 31, 845-852. (Pubitemid 19006901)
49. Attard, G., Cooper, C. S.,& De Bono, J. S. (2009). Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell, 16, 458-462. 8.
50. Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., et al. (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology, 28, 1481-1488. 20.
51. Danila, D. C., Morris, M. J., De Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., et al. (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 1496-1501. 20.
52. Logothetis, C. J., Basch, E., Molina, A., Fizazi, K., North, S. A., Chi, K. N., et al. (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, 13, 1210-1217.
53. Matsunaga, N., Kaku, T., Ojida, A., Tanaka, T., Hara, T., Yamaoka, M., et al. (2004). C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors. Bioorganic & Medicinal Chemistry, 12, 4313-4336. (Pubitemid 39055637)
54. Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., et al. (2012). Orteronel (TAK-700), a novel nonsteroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. The Journal of Steroid Biochemistry and Molecular Biology, 129, 115-128.
55. Hara, T., Kouno, J., Kaku, T., Takeuchi, T., Kusaka, M., Tasaka, A., et al. (2013). Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. The Journal of Steroid Biochemistry and Molecular Biology, 134, 80-91.
56. Dreicer, R., Agus, D. B., Bellmunt, J., De Bono, J. S., Petrylak, D., Tejura, B., et al. (2012). A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based chemotherapy [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr TPS4693).
57. Agus, D. B., Stadler, W. M., Shevrin, D. H., Hart, L., Macvicar, G. R., Hainsworth, J. D., et al. (2012). Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. [abstract]. Journal of Clinical Oncology, 50, 50-51. 30, 2012 (suppl 5; abstr 98).
58. Handratta, V. D., Vasaitis, T. S., Njar, V. C. O., Gediya, L. K., Kataria, R., Chopra, P., et al. (2005). Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry, 48, 2972-2984. 21.
59. Vasaitis, T., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., et al. (2008). Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics, 7, 2348-2357.
60. DeVore, N. M., & Scott, E. E. (2012). Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature, 482(7383), 116-119.
61. Bruno, R., Lu, J.-F., Sun, Y.-N., & Claret, L. (2011). A modeling and simulation framework to support early clinical drug development decisions in oncology. Journal of Clinical Pharmacology, 51, 6-8.
62. Schayowitz, A., Sabnis, G., Njar, V. C. O., & Brodie, A. M. H. (2008). Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics, 7, 121-132.
63. Montgomery, R. B., Eisenberger, M. a., Rettig, M., Chu, F., Pili, R., Stephenson, J., et al. (2012). Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4665). 2012.
64. Eisner, J. R., Aboott, D., I. M. B, Rafferty, S. W., Schotzinger, R. J. (2012). Assessment of Steroid Hormones Upstream of P450c17 (CYP17) in Chemically Castrate Male Rhesus Monkeys Following Treatment with the CYP17 Inhibitors VT-464 and Abiraterone Acetate (AA) [abstract]. Endocrine Reviews, 2012; Vol 33 (03-MeetingAbstracts): Sat 266.
65. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Wongvipat, J., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324, 787-790.
66. Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. a., et al. (2013). Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife, 2, e00499.
67. Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., et al. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 375, 1437-1446.
68. Treiman, D. M. (2001). GABAergic mechanisms in epilepsy. Epilepsia, 42(Suppl 3), 8-12.
69. Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., et al. (2012). ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research, 72, 1494-1503.
70. Rathkopf, D. E., Morris, M. J., Danila, D. C., Slovin, S., Steinbrecher, J., Arauz, G., et al. (2012). A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4548). 2012.
71. Smith, M., Antonarakis, E. S., Ryan, C. J., Berry, W., Shore, N., Liu, G., et al. (2012) Arn-509 in men with high risk non-metastatic castration-resistant prostate cancer [abstract]. Annals of Oncology, 23 (suppl 9) abst 920.
72. Rathkopf, D. E., Antonarakis, E. S., Shore, N., Tutrone, R., Amlukai, J., Ryan, C. J., et al. (2012). Arn-509 in men with metastatic castration-resistant prostate cancer (CRPC) [abstract]. Annals of Oncology, 23 (suppl 9) abst 964.
73. Bradbury, R. H., Acton, D. G., Broadbent, N. L., Brooks, a. N., Carr, G. R., Hatter, G., et al. (2013). Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorganic & Medicinal Chemistry Letters, 23, 1945-1948.
74. Loddick, S. a., Bradbury, R., Broadbent, N., Campbell, H., Gaughan, L., Growcott, J., et al. (2012). Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer [abstract]. Cancer Research, 72, 3848-3848.
75. Omlin, A., Jones, R. J., vn der Noll, R., Graham, J., Ong, M., Schellens, J. H. M., et al. (2013). A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC) [abstract]. Journal of Clinical Oncology, 31, 2013 (suppl; abstr 4511).
76. Massard, C., James, N., Culine, S., Jones, R., Vuorela, A., Mustonen, M., et al. (2012). ARADES trial: a first- in-man, openlabel, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract]. Annals of Oncology, 23 (suppl 9) abst LBA25.
77. Attar, R. M., Jure-Kunkel, M., Balog, A., Cvijic, M. E., Dell-John, J., Rizzo, C. A., et al. (2009). Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Research, 69, 6522-6530.
78. Rathkopf, D., Liu, G., Carducci, M. A., Eisenberger, M. A., Anand, A., Morris, M. J., et al. (2011). Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical Cancer Research, 17, 880-887.
79. Georget, V., Térouanne, B., Nicolas, J.-C., & Sultan, C. (2002). Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry, 41, 11824-11831.
80. Prescott, J., & Coetzee, G. A. (2006). Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Letters, 231, 12-19.
81. Saporita, A. J., Ai, J., & Wang, Z. (2007). The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate, 67, 509-520. (Pubitemid 46536944)
82. Tsui, K.-H., Feng, T.-H., Lin, C.-M., Chang, P.-L., Juang, H.-H. (2008). Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. Journal of Andrology, 29, 661-668.
83. Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., Bubley, G., et al. (2011). Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology, 78, 626-630.
84. Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R., Rennie, P., et al. (2007). Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research, 67, 10455-10465. (Pubitemid 350070821)
85. Rocchi, P., Beraldi, E., Ettinger, S., Fazli, L., Vessella, R. L., Nelson, C., et al. (2005). Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Research, 65, 11083-11093. (Pubitemid 41713379)
86. Andrieu, C., Taieb, D., Baylot, V., Ettinger, S., Soubeyran, P., De-Thonel, A., et al. (2010). Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene, 29, 1883-1896.
87. Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., et al. (2013). Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Research, 73, 3109-3119.
88. Chi, K. N., Hotte, S. J., Ellard, S. L., Gingerich, J., Joshua, A., Yu, E. Y., et al. (2012). A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4514). 2012.
89. Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D., Eigl, B. J., Tannock, I., et al. (2010). Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 4247-4254.
90. Chi, K. N., Siu, L. L., Hirte, H., Hotte, S. J., Knox, J., Kollmansberger, C., et al. (2008). A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clinical Cancer Research, 14, 833-839. (Pubitemid 351231167)
91. Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., et al. (2011). Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research, 71, 6019-6029.
92. Cook, P. D. (1999). Making drugs out of oligonucleotides: a brief review and perspective. Nucleosides& Nucleotides, 18, 1141-1162.
93. Gleave, M. E., & Monia, B. P. (2005). Antisense therapy for cancer. Nature Reviews Cancer, 5, 468-479.
94. Zhang, Y., Castaneda, S., Dumble, M., Wang, M., Mileski, M., Qu, Z., et al. (2011). Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Molecular Cancer Therapeutics, 10, 2309-2319.
95. Bianchini, D., Omlin, A., Pezaro, C., Mukherji, D., Lorente Estelles. D., Zivi, A., et al. (2013). First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC) [abstract]. Journal of Clinical Oncology, 31 (suppl; abstr 5052).
96. Richards, J., Lim, A. C., Hay, C. W., Taylor, A. E., Wingate, A., Nowakowska, K., et al. (2012). Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Research, 72, 2176-2182.
97. Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., et al. (2013). Antitumour activity of abiraterone acetate againstmetastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology, 24(7), 1807-1812.
98. Noonan, K. L., North, S., Bitting, R. L., Armstrong, a. J., Ellard, S. L., & Chi, K. N. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology, 24(7), 1802-1807.
99. Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
100. Mediwala, S. N., Sun, H., Szafran, A. T., Hartig, S. M., Sonpavde, G., Hayes, T. G., et al. (2013). The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate, 73, 267-277.
101. Trotta, A. P., Need, E. F., Selth, L. A., Chopra, S., Pinnock, C. B., Leach, D. A., et al. (2013). Knockdown of the co-chaperone SGTA results in the suppression of androgen and PI3K/AKT signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823.
102. Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., et al. (2007). FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British Journal of Cancer, 97, 678-685. (Pubitemid 47339893)
103. Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. (2006). Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Research, 66, 7929-7933. (Pubitemid 44299155)
104. Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., et al. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell, 19, 575-586.
105. Mostaghel, E. a., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., et al. (2007). Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research, 67, 5033-5041. (Pubitemid 46910214)
106. Smith, M., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., et al. (2013). Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). [abstract]. Journal of Clinical Oncology, 31, 2013 (suppl; abstr 5001).
107. Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., Mason, M. D. (2006). Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Systematic Reviews. doi: 10.1002/14651858.CD006019.pub2
108. Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., et al. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. International Journal of Radiation Oncology Biology and Physics, 61, 1285-1290. (Pubitemid 40470408)
109. Bolla, M., De Reijke, T. M., Van Tienhoven, G., Oddens, J., Poortmans, P. M. P., Gez, E., et al. (2009). Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine, 360, 2516-2527.
110. McGuire, S. E., Lee, A. K., Cerne, J. Z., Munsell, M. F., Levy, L. B., Kudchadker, R. J., et al. (2013). PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. International Journal of Radiation Oncology Biology and Physics, 85, e39-e46.
111. Taplin, M.-E., Montgomery, R. B., Logothetis, C. J., Bubley, G. J., Richie, J. P., Dalkin, B. L., et al. (2012). Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4521).